127 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
Estimated reimbursement rate compared to reimbursement agent
Risk-adjusted discount rates
The change in fair value between December 31, 2023 and March … are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
and Immedica dated March 2021.
The milestone payments under the Immedica APA are contingent on formal reimbursement decisions by national authorities … -party coverage and reimbursement policies.
We may face criminal liability or other consequences for violations of U.S. and foreign trade regulations
POS AM
xhob78 qxoly
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
hx5c7qeoqu1fm
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
gasuc34mdifh1os
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
1cjeol oy
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-3.1
xr3a1p46w8w9ez408
5 Feb 24
Entry into a Material Definitive Agreement
7:36am